- A systematic review and meta-analysis suggest that secukinumab (Cosentyx) 150 mg and 300 mg are associated with similar risk for adverse events (AEs) in patients with moderate to severe plaque psoriasis.
Why this matters
- This meta-analysis supports the safety of secukinumab at both doses.
- Secukinumab 150 mg and 300 mg were associated with similar risk for any AE (risk ratio [RR], 1.00; P=.94), serious AEs (RR, 1.04; P=.82), and AEs leading to drug discontinuation (RR, 0.98; P=.92).
- Secukinumab 150 mg and 300 mg were associated with similar risk for infection/infestation (RR, 1.11; P=.09), nasopharyngitis (RR, 1.05; P=.55), headache (RR, 0.92; P=.60), diarrhea (RR, 1.14; P=.55), pruritus (RR, 0.82; P=.33), arthralgia (RR, 0.96; P=.83), upper respiratory tract infection (RR, 0.98; P=.89), hypertension (RR, 1.22; P=.31), nausea (RR, 1.39; P=.42), and cough (RR, 1.46; P=.34).
- 7 studies with 2361 participants were included.
- Funding: None.
- Some heterogeneity between studies.